Format

Send to

Choose Destination
Theranostics. 2017 Feb 26;7(5):1062-1071. doi: 10.7150/thno.17908. eCollection 2017.

Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis.

Author information

1
College of Pharmaceutical Science, Jilin University, Changchun 130021, China.
2
CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
3
University of Chinese Academy of Sciences, Beijing 100049, China.
4
Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China.
5
QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, QLD 4029, Australia.
6
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD21231, USA.

Abstract

Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

KEYWORDS:

Tumor associated platelets; liposomal nanoparticle; metastatic inhibition.; tumor metastasis

PMID:
28435448
PMCID:
PMC5399576
DOI:
10.7150/thno.17908
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center